The present mainstay of asthma treatment is to prescribe maintenance daily inhaled corticosteroids in all patients with asthma who have more than intermittent symptoms, with the addition of maintenance longacting (32 agonists in cases of insufficient asthma control.1 On top of low-dose inhaled ...
Overview Risks Diagnosis Treatment Management What is moderate or severe persistent asthma?Moderate or severe persistent asthma means you have asthma symptoms every day. You may also need to use your rescue inhaler daily to treat shortness of breath. Your normal activities are affected by wheezing,...
Montelukast is as efficient as doubling the dose of ICS on asthma symptoms in cases of inadequate control with low-dose ICS. Combined with ICS, it can lead to better control of asthma and potentially to ICS sparing. Given the efficacy, tolerance and long-term treatment compliance of ...
OBJECTIVE: The purpose of the study was to evaluate the dose-response relationships of the inhaled corticosteroid budesonide in a double blind crossover study in 19 children with moderate and severe asthma. METHODS: A 2-week placebo treatment period (run-in) was followed by three 4-week treatme...
despite the availability of asthma treatment guidelines27 and effective treatments, asthma still remains undertreated.28 There is evidence supporting the view that starting with a moderate dose of ICS and then reducing the dose once asthma control has been achieved is as effective as starting with ...
not.Materials and methods: Thirty two adult asthmatics (17 male and 15 female) completed a 10 week trial consisting of a 1 week single blind run in period, during which placebo (250 mg capsule of lactose 3 times a day) was added to usual treatment (inhaled beclomethasone diproprionate ...
Theophylline has shown itself to be a useful bronchodilator in the treatment of asthma, although its use has been restricted of late due to its lesser potency and greater side effects when compared with beta-adrenergic inhalants. The objective of our study is to evaluate its clinical effectiveness...
New simplified treatment approaches may offer a solution and assist physicians to achieve overall asthma control. One such treatment approach, which is recommended in the GINA guidelines, is budesonide/formoterol for both maintenance and reliever therapy. This treatment strategy significantly reduces the ...
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274-312.Pub...
The 4 most common predefined risk factors or comorbidities in both treatment groups at screening were obesity, age of 55 years or older, diabetes requiring medication, and moderate to severe asthma. Most patients (59%) had symptoms for 3 or fewer days. Presenting symptoms were similar between ...